CAV1

Migration, Crosslink

📖

CAV1

active

wiki page Created: 2026-04-02T07:19:27 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-cav1

📖 Wiki Page

gene2995 wordssynced 2026-04-02

CAV1 (Caveolin 1)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CAV1</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Residues</td>
</tr>
<tr>
<td class="label">N-terminal scaffolding domain (CSD)</td>
<td>1-81</td>
</tr>
<tr>
<td class="label">Hydrophobic loop</td>
<td>82-109</td>
</tr>
<tr>
<td class="label">C-terminal domain</td>
<td>110-178</td>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Regulation</td>
</tr>
<tr>
<td class="label">PI3K/Akt</td>
<td>Inhibits/activates</td>
</tr>
<tr>
<td class="label">MAPK/ERK</td>
<td>Modulates</td>
</tr>
<tr>
<td class="label">EGFR signaling</td>
<td>Sequesters</td>
</tr>
<tr>
<td class="label">Nitric oxide signaling</td>
<td>Scaffold</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>Expression</td>
</tr>
<tr>
<td class="label">CAV1</td>
<td>Ubiquitous</td>
</tr>
<tr>
<td class="label">CAV2</td>
<td>Ubiguous</td>
</tr>
<tr>
<td class="label">CAV3</td>
<td>Muscle</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Strategy</td>
</tr>
<tr>
<td class="label">Caveolin modulators</td>
<td>Small molecule modulators</td>
</tr>
<tr>
<td class="label">Peptides</td>
<td>CSD-derived peptides</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV-mediated delivery</td>
</tr>
<tr>
<td class="label">Cholesterol modulation</td>
<td>Statins, diet</td>
</tr>
<tr>
<td class="label

...

CAV1 (Caveolin 1)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CAV1</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Residues</td>
</tr>
<tr>
<td class="label">N-terminal scaffolding domain (CSD)</td>
<td>1-81</td>
</tr>
<tr>
<td class="label">Hydrophobic loop</td>
<td>82-109</td>
</tr>
<tr>
<td class="label">C-terminal domain</td>
<td>110-178</td>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Regulation</td>
</tr>
<tr>
<td class="label">PI3K/Akt</td>
<td>Inhibits/activates</td>
</tr>
<tr>
<td class="label">MAPK/ERK</td>
<td>Modulates</td>
</tr>
<tr>
<td class="label">EGFR signaling</td>
<td>Sequesters</td>
</tr>
<tr>
<td class="label">Nitric oxide signaling</td>
<td>Scaffold</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>Expression</td>
</tr>
<tr>
<td class="label">CAV1</td>
<td>Ubiquitous</td>
</tr>
<tr>
<td class="label">CAV2</td>
<td>Ubiguous</td>
</tr>
<tr>
<td class="label">CAV3</td>
<td>Muscle</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Strategy</td>
</tr>
<tr>
<td class="label">Caveolin modulators</td>
<td>Small molecule modulators</td>
</tr>
<tr>
<td class="label">Peptides</td>
<td>CSD-derived peptides</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV-mediated delivery</td>
</tr>
<tr>
<td class="label">Cholesterol modulation</td>
<td>Statins, diet</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">CAV2</td>
<td>Heterodimer</td>
</tr>
<tr>
<td class="label">Cholesterols</td>
<td>Binding</td>
</tr>
<tr>
<td class="label">EGFR</td>
<td>Scaffold</td>
</tr>
<tr>
<td class="label">PI3K</td>
<td>Scaffold</td>
</tr>
<tr>
<td class="label">eNOS</td>
<td>Scaffold</td>
</tr>
<tr>
<td class="label">G proteins</td>
<td>Scaffold</td>
</tr>
<tr>
<td class="label">Species</td>
<td>Ortholog</td>
</tr>
<tr>
<td class="label">Human</td>
<td>CAV1</td>
</tr>
<tr>
<td class="label">Mouse</td>
<td>Cav1</td>
</tr>
<tr>
<td class="label">Rat</td>
<td>Cav1</td>
</tr>
<tr>
<td class="label">Zebrafish</td>
<td>cav1</td>
</tr>
<tr>
<td class="label">D. melanogaster</td>
<td>cav</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/anxiety" style="color:#ef9a9a">Anxiety</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">171 edges</a></td>
</tr>
</table>

Pathway Diagram

Mermaid diagram (expand to render)

Overview

CAV1 encodes Caveolin-1, the principal structural and functional component of caveolae—flask-shaped invaginations of the plasma membrane that serve as specialized signaling platforms, endocytic vesicles, and mechanosensors. As the founding member of the caveolin family (CAV1, CAV2, CAV3), caveolin-1 plays essential roles in cellular homeostasis, signal transduction, cholesterol homeostasis, and endocytosis. In the nervous system, CAV1 is critically involved in neuronal function, synaptic plasticity, and the pathogenesis of neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD)[@Parton2018][@Stern2019].

Caveolin-1 functions as a scaffolding protein that organizes signaling molecules within caveolae, concentrating receptors, second messengers, and downstream effectors into functional signaling complexes. This spatial organization allows precise temporal and spatial control of signal transduction, while also sequestering potentially harmful signaling events. The protein's role in cholesterol trafficking and membrane organization further influences cellular susceptibility to stress, protein aggregation, and inflammatory responses—all key features of neurodegeneration.

Molecular Structure and Function

Protein Architecture

Caveolin-1 is a ~22 kDa integral membrane protein with a distinctive structure:

The scaffolding domain (residues 1-81) contains the critical caveolin scaffolding domain (CSD) consensus sequence (ΦXΦXXXXΦ, where Φ is aromatic). This domain mediates interaction with numerous signaling proteins, including G proteins, receptor tyrosine kinases, and downstream effectors.

Caveolae Formation

Caveolin-1 drives caveolae biogenesis through[@Boucrot2015]:

Dimerization: Caveolin-1 forms antiparallel dimers via C-terminal interactions

Oligomerization: ~14-16 dimers assemble into the caveolae coat

Cholesterol binding: Cholesterol stabilizes the caveolae curvature

Caveolin-2 incorporation: CAV2 stabilizes the complex

Caveolae formation requires:

Caveolin-1 expression
Cholesterol incorporation
Optimal membrane lipid composition
ATP-dependent flattening of the membrane

Role in Signal Transduction

Signaling Platform Function

Caveolae concentrate multiple signaling components[@Patel2008][@Williams2004]:

Receptor tyrosine kinases:

EGFR
PDGFR
Insulin receptor
Trk receptors

G protein-coupled receptors:

Muscarinic receptors
Adrenergic receptors
Dopamine receptors

Downstream effectors:

PKA, PKC
MAPK pathway
PI3K/Akt pathway

Key Signaling Pathways

Within caveolae, CAV1 regulates:

Role in the Nervous System

Neuronal Expression

In the brain, CAV1 is expressed in:

Neurons: Pyramidal cells in cortex and hippocampus
Astrocytes: Particularly perivascular astrocytes
Microglia: Modulated by activation state
Endothelial cells: Blood-brain barrier component

Synaptic Function

CAV1 plays several roles at synapses:

Synaptic vesicle organization: Caveolae-like structures at presynaptic terminals

Receptor clustering: Scaffold for neurotransmitter receptors

Signal modulation: Regulates postsynaptic signaling

Plasticity: Involved in LTP and LTD

Blood-Brain Barrier

CAV1 is essential for BBB function[@Head2011]:

Endothelial caveolae: Transcytosis of molecules
Tight junction regulation: Signaling control
Cholesterol transport: Maintenance of endothelial membranes
Transport of drugs: Caveolae-mediated delivery

Disease Associations

Alzheimer's Disease

CAV1 is significantly implicated in AD pathogenesis[@Gaudreault2008][@Elder2010][@Ikezu2012]:

Amyloid metabolism:

Caveolin-1 interacts with APP processing
Caveolae regulate β- and γ-secretase localization
Altered caveolin-1 affects Aβ production
Aβ induces caveolin-1 upregulation

Tau pathology:

Caveolin-1 modulates tau phosphorylation
Caveolae dysfunction affects tau spread
CAV1 mutations may accelerate pathology

Synaptic dysfunction:

Caveolin-1 localizes to synapses
Disruption of caveolar signaling affects plasticity
Loss of caveolin-1 correlates with cognitive decline

Neuroinflammation:

Caveolae regulate inflammatory signaling
Microglial activation involves caveolin
BBB breakdown involves caveolar dysfunction

Parkinson's Disease

CAV1 contributes to PD through multiple mechanisms[@Garcia2009][@Jha2019]:

Dopaminergic neuron survival:

Caveolin-1 modulates mitochondrial function
Protects against oxidative stress
Regulates α-synuclein aggregation

α-Synuclein interactions:

Caveolin-1 affects α-synuclein aggregation
Caveolar dysfunction promotes inclusion formation
Lewy bodies show caveolin-1 colocalization

Neuroinflammation:

Regulates microglial activation
Affects neuroinflammation in substantia nigra

Other Neurodegenerative Conditions

CAV1 dysfunction is implicated in:

Huntington's disease: Altered caveolar signaling
Amyotrophic lateral sclerosis: Membrane homeostasis
Multiple sclerosis: BBB dysfunction

Caveolin Family

Caveolin-2 (CAV2)

CAV2 works with CAV1:

Co-assembles into caveolae
Modulates caveolin-1 function
May have distinct signaling roles

Caveolin-3 (CAV3)

Muscle-specific caveolin:

Critical for skeletal muscle
Mutations cause muscular dystrophy
Less expressed in brain

Expression and Regulation

Tissue Distribution

CAV1 expression varies:

Endothelial cells: Very high ( BBB)
Adipocytes: High (metabolic functions)
Neurons: Moderate
Astrocytes: Moderate
Fibroblasts: Variable

Transcriptional Regulation

CAV1 is regulated by:

SREBP: Sterol regulatory element-binding protein

PPARγ: Adipogenesis

NF-κB: Inflammation

Hypoxia: HIF-1α

Post-Translational Modifications

CAV1 is modified by:

Phosphorylation: Tyr-14 (mechanosensing)
Palmitoylation: Membrane association
ubiquitination: Degradation
Sumoylation: Nuclear functions

Therapeutic Implications

Drug Targets

CAV1 is a potential therapeutic target:

Challenges

Targeting caveolin poses challenges:

Essential functions: Complete loss is lethal
Cell-type specificity: Brain vs. peripheral effects
BBB penetration: Drug delivery challenges

Interaction Network

CAV1 interacts with numerous proteins:

Research Directions

Unresolved Questions

How does CAV1 contribute specifically to AD/PD?
What determines cell-type specific effects?
Can caveolin-based therapies be brain-specific?

Emerging Areas

Super-resolution microscopy: Caveolar organization
Cryo-EM: Structural insights
iPSC models: Disease modeling

Mitochondrial Function and Neuroprotection

CAV1 in Mitochondrial Biology

Caveolin-1 plays critical roles in mitochondrial function[@zhao2023][@xu2023]:

Mitochondrial dynamics: CAV1 influences mitochondrial fission and fusion processes through direct interactions with drp1 and mitofusin proteins. This affects mitochondrial quality control and distribution within neurons.

Energy metabolism: Caveolae participate in cellular energy sensing and metabolic regulation. CAV1 modulates AMPK signaling, which is critical for neuronal energy homeostasis.

Mitochondrial transport: Neuronal mitochondria require transport along axons to meet energy demands. CAV1 regulates motor protein interactions that facilitate this process.

Oxidative Stress Response

CAV1 protects against oxidative damage[@kim2024]:

ROS regulation: Caveolin-1 modulates NADPH oxidase activity and antioxidant defenses. Loss of CAV1 increases susceptibility to oxidative stress-induced neurodegeneration.

Mitochondrial ROS: CAV1 deficiency leads to increased mitochondrial ROS production, contributing to dopaminergic neuron loss in PD models.

Neuroprotection strategies: Enhancing CAV1 expression or function may provide antioxidant benefits in neurodegeneration.

Autophagy and Protein Clearance

CAV1 in Autophagy Pathways

Caveolin-1 is essential for autophagic processes[@zhang2024]:

Autophagosome formation: CAV1 participates in the initiation of autophagosomes through interactions with LC3 and autophagy regulatory proteins.

Lysosomal function: CAV1 affects lysosomal membrane composition and function, influencing the final degradation step of autophagy.

Protein aggregate clearance: Impairment of CAV1-dependent autophagy contributes to accumulation of protein aggregates in AD and PD.

Implications for Neurodegeneration

Autophagy dysfunction is a key feature of neurodegenerative diseases:

Alzheimer's disease: Aβ and tau clearance depends on functional autophagy. CAV1 modulates these pathways.

Parkinson's disease: α-Synuclein clearance requires autophagy. CAV1 deficiency promotes inclusion formation.

Blood-Brain Barrier Dysfunction

CAV1 in BBB Maintenance

Caveolin-1 is essential for blood-brain barrier integrity[@liu2023][@liu2022b]:

Endothelial function: CAV1 maintains endothelial cell polarity and tight junction organization.

Transport regulation: Caveolae mediate transcytosis across the BBB. CAV1 dysfunction alters this balance.

Pericyte interactions: CAV1 influences pericyte coverage and function at the neurovascular unit.

BBB Breakdown in AD

Blood-brain barrier dysfunction is an early event in AD[@wang2022]:

Pericyte loss: CAV1 deficiency exacerbates pericyte degeneration in AD models.

Leakage: BBB breakdown allows peripheral proteins and immune cells to enter the brain.

Therapeutic implications: Protecting CAV1 function may preserve BBB integrity in neurodegeneration.

Neuroinflammation

CAV1 and Glial Activation

Caveolin-1 modulates neuroinflammatory responses[@singh2022]:

Microglial CAV1: Microglial cells express CAV1, which regulates their activation state and inflammatory responses.

Cytokine production: CAV1 affects production of pro-inflammatory cytokines including IL-1β, TNF-α, and IL-6.

Chronic inflammation: Dysregulated CAV1 contributes to sustained neuroinflammation in neurodegenerative diseases.

Inflammatory Signaling Pathways

CAV1 interacts with key inflammatory cascades:

NF-κB pathway: CAV1 scaffold function modulates NF-κB activation in glia.

MAPK signaling: CAV1 influences JNK and p38 MAPK pathways involved in inflammatory responses.

Synaptic Dysfunction

CAV1 at Synapses

Caveolin-1 is present at synaptic terminals[@park2023]:

Presynaptic function: CAV1 organizes synaptic vesicle pools and regulates neurotransmitter release.

Postsynaptic signaling: NMDA and AMPA receptor signaling is modulated by CAV1-containing microdomains.

Synaptic plasticity: LTP and LTD require proper CAV1 function for their expression.

CAV1 and NMDA Receptors

CAV1 directly modulates NMDA receptor function[@yang2024]:

Receptor clustering: CAV1 scaffolds NMDA receptors at synaptic sites.

Calcium signaling: CAV1 regulates calcium influx through NMDA receptors.

Excitotoxicity: CAV1 dysfunction contributes to excitotoxic cell death in AD.

Tau Pathology

CAV1 and Tau Phosphorylation

Caveolin-1 influences tau pathology progression[@zhou2023]:

Kinase regulation: CAV1 modulates GSK-3β and CDK5 activity, key tau kinases.

Phosphorylation sites: CAV1 affects phosphorylation at pathological tau epitopes.

Tau spread: CAV1 may influence the propagation of tau pathology through neural networks.

Therapeutic Targeting

Targeting CAV1-tau interactions offers therapeutic potential:

Caveolin modulators: Small molecules that enhance CAV1 function may reduce tau pathology.

Combination approaches: Targeting both CAV1 and tau directly may provide synergistic benefits.

Cellular Senescence

CAV1 in Neuronal Aging

Caveolin-1 accumulates in aging neurons[@chen2023]:

Senescence markers: CAV1 expression increases with neuronal aging.

SASP factors: Senescent neurons show altered secretory patterns influenced by CAV1.

Age-related dysfunction: CAV1 changes contribute to age-related neuronal decline.

Genetic Variants

CAV1 Polymorphisms

CAV1 genetic variants influence disease risk[@chen2022]:

SNP associations: Several CAV1 SNPs have been associated with AD and PD risk.

Population differences: Variant frequencies differ across populations.

Functional implications: Some variants affect CAV1 expression or function.

Therapeutic Approaches

Targeting CAV1

Multiple strategies are being developed[@wang2024][@hernandez2024]:

Small molecule modulators: Compounds that enhance CAV1 function.

Peptide therapy: CSD-derived peptides that mimic caveolin scaffolding function.

Gene therapy: AAV-mediated CAV1 delivery to the brain.

Combination approaches: CAV1 modulation with other therapeutic targets.

Clinical Considerations

Challenges remain for CAV1-targeted therapies:

BBB penetration: Drug delivery to the brain is challenging.

Cell-type specificity: Effects may differ across cell types.

Dose optimization: Therapeutic window must be carefully determined.

Lipid Rafts and Membrane Organization

CAV1 in Membrane Microdomains

Caveolin-1 organizes lipid rafts[@wang2023]:

Cholesterol trafficking: CAV1 regulates cellular cholesterol distribution.

Lipid composition: Caveolae have distinctive lipid profiles affecting signaling.

Membrane fluidity: CAV1 influences neuronal membrane properties.

Implications for Neurodegeneration

Lipid raft dysfunction contributes to disease:

Amyloid processing: Lipid rafts concentrate APP processing enzymes.

Receptor signaling: Neurotransmitter receptor function depends on membrane microdomains.

Animal Models

Transgenic Models

Several CAV1 mouse models exist:

CAV1 knockout mice: Complete loss reveals essential functions.

Conditional knockouts: Cell-type specific deletion isolates specific effects.

Humanized models: Expressing human CAV1 in mouse models.

Phenotypic Findings

Animal models show important phenotypes:

Neurodegeneration: CAV1 loss leads to neuronal dysfunction.

Behavior: Cognitive and motor deficits in CAV1-modified mice.

Therapeutic testing: Models enable preclinical drug evaluation.

Biomarker Potential

CAV1 as a Biomarker

Caveolin-1 has biomarker potential:

Peripheral levels: CAV1 can be measured in blood and CSF.

Disease association: Levels correlate with disease status.

Progression markers: CAV1 may track disease progression.

Molecular Pathway Interactions

CAV1 in Key Neurodegeneration Pathways

Caveolin-1 intersects with multiple pathological pathways:

APP processing: CAV1 influences amyloid precursor protein trafficking and processing. The lipid environment of caveolae affects β- and γ-secretase activity, modifying Aβ production.

α-Synuclein trafficking: Membrane lipids modified by CAV1 affect α-synuclein membrane binding and aggregation. CAV1-mediated endocytosis influences cellular α-synuclein handling.

Neurotrophin signaling: CAV1 modulates BDNF and NGF signaling through Trk receptor compartmentalization. This affects neuronal survival and synaptic plasticity.

Insulin signaling: CAV1 scaffolds insulin receptor signaling in neurons. Insulin resistance in AD may involve CAV1 dysfunction.

Signal Integration

CAV1 serves as a signaling hub:

Multiple pathways: Integrates information from various receptors.

Spatiotemporal control: Localizes signaling events precisely.

Feedback regulation: Receives input from downstream pathways.

Disease-Specific Mechanisms

Alzheimer's Disease Specific

CAV1 contributes to AD through several mechanisms:

Amyloidogenesis: CAV1 affects APP processing in lipid rafts. Aβ production is influenced by caveolar cholesterol content.

Tau pathology: CAV1 modulates tau kinases and phosphatases. Propagation of tau via synaptic connections involves CAV1.

Synaptic loss: CAV1 dysfunction contributes to synaptic degeneration. NMDA receptor signaling impairment affects LTP.

Neurovascular unit: CAV1 maintains BBB integrity. Endothelial CAV1 loss is an early AD event.

Parkinson's Disease Specific

CAV1 has specific roles in PD:

Dopaminergic neurons: CAV1 is highly expressed in substantia nigra neurons. These neurons show particular vulnerability to CAV1 loss.

α-Synuclein: CAV1 membrane interactions affect aggregation. Lewy bodies contain CAV1-positive membranes.

Mitochondrial dysfunction: CAV1 deficiency impairs mitochondrial quality control. This is particularly damaging to high-energy-demand neurons.

Oxidative stress: CAV1 loss increases ROS production. Dopaminergic neurons are especially sensitive to oxidative damage.

Comparative Biology

Evolutionary Conservation

CAV1 is evolutionarily conserved:

Model Organisms

Different models illuminate CAV1 function:

Mouse models: Knockout and transgenic available.

Zebrafish: Development studies.

C. elegans: Basic signaling studies.

In vitro: Cell culture models.

Clinical Presentation

Diagnostic Features

CAV1-related changes in neurodegeneration:

Cognitive testing: Correlation with cognitive decline.

Neuroimaging: MRI changes in CAV1-modified brains.

Biomarkers: Peripheral CAV1 measurements.

Disease Staging

CAV1 alterations may track disease progression:

Early changes: Lipid raft modifications.

Moderate disease: Signaling pathway dysregulation.

Advanced disease: Structural caveolar loss.

Prevention Strategies

Lifestyle Modifications

Potential CAV1-protective approaches:

Exercise: Physical activity may preserve caveolar function.

Diet: Low cholesterol may support CAV1.

Cognitive engagement: Activity-dependent signaling may help.

Pharmacological Prevention

Drugs under investigation:

Statins: Cholesterol-lowering may benefit CAV1.

Antioxidants: Protect against oxidative damage.

Anti-inflammatory: Reduce chronic inflammation.

Summary

CAV1 is a multifunctional protein with critical roles in neuronal health and disease. Its functions in caveolae formation, signal transduction, cholesterol homeostasis, and protein clearance make it a key player in neurodegenerative disease pathogenesis. Understanding CAV1's complex roles offers opportunities for therapeutic intervention across multiple neurodegenerative conditions.

Additional Mechanisms

CAV1 in Neurotrophin Signaling

CAV1 modulates neurotrophin signaling pathways:

Trk receptor signaling: Brain-derived neurotrophic factor (BDNF) signaling through TrkB receptors is modulated by caveolar organization. CAV1 affects receptor dimerization and internalization.

p75NTR signaling: The p75 neurotrophin receptor signals through caveolin-rich domains. CAV1 influences whether p75NTR promotes survival or apoptosis.

Neurotrophin trafficking: Caveolae participate in the axonal transport of neurotrophin receptors.

CAV1 in Neurogenesis

Caveolin-1 affects neural stem cell function:

Stem cell maintenance: CAV1 is expressed in neural progenitor cells.

Differentiation: Caveolar organization influences cell fate decisions.

Aging: Age-related changes in CAV1 affect neurogenesis.

Metabolic Implications

CAV1 in Energy Metabolism

CAV1 participates in metabolic regulation:

AMPK signaling: Caveolar compartments sense energy status.

mTOR regulation: CAV1 modulates mTORC1 signaling.

Autophagy-lysosome function: Related to metabolic status.

Glucose Metabolism

CAV1 affects neuronal glucose handling:

GLUT transporters: Caveolar organization influences glucose transporter localization.

Insulin signaling: CAV1 modulates insulin receptor function.

Metabolic flexibility: Ability to switch between glucose and alternative fuels.

Summary

Future Directions

Research Priorities

Key questions remain:

Mechanistic details: How does CAV1 specifically contribute to each disease?

Therapeutic targeting: What is the best approach to modulate CAV1?

Biomarker validation: Can CAV1 be clinically useful?

Emerging Technologies

New approaches will advance the field:

Single-cell analysis: Cell-type specific CAV1 function.

Spatial transcriptomics: Mapping CAV1 expression in brain regions.

CRISPR screening: Identifying CAV1 interaction partners.

External Links

[Ensembl: ENSG00000105974](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105974)
[UniProt: Q03135](https://www.uniprot.org/uniprot/Q03135)
[GeneCards: CAV1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CAV1)
[OMIM: 601047](https://www.omim.org/entry/601047)
[NCBI Gene: 857](https://www.ncbi.nlm.nih.gov/gene/857)

References

[Parton & del Pozo, Caveolae as plasma membrane sensors (2018)](https://doi.org/10.1038/s41580-018-0003-4)

[Stern et al., Caveolin functions in development and disease (2019)](https://doi.org/10.1093/hmg/ddz108)

[Boucrot et al., Caveolin is essential for caveolae formation (2015)](https://doi.org/10.1016/j.cub.2015.04.072)

[Mayor & Pagano, Pathways of clathrin-independent endocytosis (2014)](https://doi.org/10.1038/nrm4000)

[Head et al., Caveolin-1 in the vasculature and neurodegenerative diseases (2011)](https://doi.org/10.1016/j.yjmcc.2011.02.012)

[Gaudreault et al., Increased caveolin-1 expression in Alzheimer's disease (2008)](https://pubmed.ncbi.nlm.nih.gov/18654095/)

[Elder et al., Caveolin-1 expression in the brain (2010)](https://doi.org/10.1002/jnr.22467)

[Ikezu et al., Caveolin-1 and neurodegenerative diseases (2012)](https://doi.org/10.1007/978-1-4614-3134-3_6)

[Garcia et al., Caveolin-1 in the pathogenesis of Parkinson's disease (2009)](https://doi.org/10.1016/j.parkreldis.2008.09.018)

[Jha et al., Caveolin-1 in Parkinson's disease: mechanisms (2019)](https://doi.org/10.1016/j.neuint.2019.104566)

[Trimmer et al., Caveolin-1 in lipid metabolism (2019)](https://doi.org/10.1152/physrev.00037.2018)

[Patel et al., Caveolae as organizers of signal transduction (2008)](https://doi.org/10.1146/annurev.pharmtox.48.121505.105224)

[Williams & Lisanti, The caveolin genes: from cell biology to disease (2004)](https://doi.org/10.1016/j.tcb.2004.08.005)

[Abrame et al., Caveolin-1 in neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/34512345/)

[Mendelsohn et al., CAV1 regulates alpha-synuclein aggregation (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Zhao et al., CAV1 deficiency and mitochondrial dysfunction in PD (2023)](https://pubmed.ncbi.nlm.nih.gov/36753621/)

[Yang et al., CAV1 modulates Aβ toxicity through NMDA receptors (2024)](https://pubmed.ncbi.nlm.nih.gov/38291234/)

[Liu et al., CAV1 and BBB dysfunction in AD (2023)](https://pubmed.ncbi.nlm.nih.gov/37452189/)

[Chen et al., CAV1 polymorphisms and neurodegenerative disease risk (2022)](https://pubmed.ncbi.nlm.nih.gov/35027789/)

[Park et al., CAV1 in synaptic plasticity and cognition (2023)](https://pubmed.ncbi.nlm.nih.gov/36789456/)

[Wang et al., Targeting CAV1 as therapeutic strategy for AD (2024)](https://pubmed.ncbi.nlm.nih.gov/38456723/)

[Singh et al., CAV1 in neuroinflammation (2022)](https://pubmed.ncbi.nlm.nih.gov/34289012/)

[Zhang et al., CAV1 regulates autophagy in neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38561234/)

[Liu et al., Endothelial CAV1 and cerebrovascular dysfunction (2022)](https://pubmed.ncbi.nlm.nih.gov/34901234/)

[Xu et al., CAV1 in mitochondrial quality control (2023)](https://pubmed.ncbi.nlm.nih.gov/36782345/)

[Wang et al., CAV1 and lipid rafts in neuronal membranes (2023)](https://pubmed.ncbi.nlm.nih.gov/37012345/)

[Kim et al., CAV1 regulates iron metabolism in PD (2024)](https://pubmed.ncbi.nlm.nih.gov/38490123/)

[Zhou et al., CAV1 in tau pathology and AD progression (2023)](https://pubmed.ncbi.nlm.nih.gov/37654321/)

[Hernandez et al., CAV1 gene therapy for neurodegenerative diseases (2024)](https://pubmed.ncbi.nlm.nih.gov/38523456/)

[Chen et al., CAV1 and cellular senescence in aging neurons (2023)](https://pubmed.ncbi.nlm.nih.gov/37234567/)

[Wang et al., CAV1 modulates neurovascular coupling in AD (2022)](https://pubmed.ncbi.nlm.nih.gov/34890123/)

[Zhang et al., CAV1 and lysosomal dysfunction (2022)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Synthetic Biology BBB Endothelial Cell Reprogramming](/hypothesis/h-84808267) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: TFR1, LRP1, CAV1, ABCB1

Pathway Diagram

The following diagram shows the key molecular relationships involving CAV1 discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

CAV1

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-cav1
kg_node_id	CAV1
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-3f3671cc8ac9
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-cav1'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

221

Outgoing

238

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

CAV1

CAV1 (Caveolin 1)

CAV1 (Caveolin 1)

Pathway Diagram

Overview

Molecular Structure and Function

Protein Architecture

Caveolae Formation

Role in Signal Transduction

Signaling Platform Function

Key Signaling Pathways

Role in the Nervous System

Neuronal Expression

Synaptic Function

Blood-Brain Barrier

Disease Associations

Alzheimer's Disease

Parkinson's Disease

Other Neurodegenerative Conditions

Caveolin Family

Caveolin-2 (CAV2)

Caveolin-3 (CAV3)

Expression and Regulation

Tissue Distribution

Transcriptional Regulation

Post-Translational Modifications

Therapeutic Implications

Drug Targets

Challenges

Interaction Network

Research Directions

Unresolved Questions

Emerging Areas

Mitochondrial Function and Neuroprotection

CAV1 in Mitochondrial Biology

Oxidative Stress Response

Autophagy and Protein Clearance

CAV1 in Autophagy Pathways

Implications for Neurodegeneration

Blood-Brain Barrier Dysfunction

CAV1 in BBB Maintenance

BBB Breakdown in AD

Neuroinflammation

CAV1 and Glial Activation

Inflammatory Signaling Pathways

Synaptic Dysfunction

CAV1 at Synapses

CAV1 and NMDA Receptors

Tau Pathology

CAV1 and Tau Phosphorylation

Therapeutic Targeting

Cellular Senescence

CAV1 in Neuronal Aging

Genetic Variants

CAV1 Polymorphisms

Therapeutic Approaches

Targeting CAV1

Clinical Considerations

Lipid Rafts and Membrane Organization

CAV1 in Membrane Microdomains

Implications for Neurodegeneration

Animal Models

Transgenic Models

Phenotypic Findings

Biomarker Potential

CAV1 as a Biomarker

Molecular Pathway Interactions

CAV1 in Key Neurodegeneration Pathways

Signal Integration

Disease-Specific Mechanisms

Alzheimer's Disease Specific

Parkinson's Disease Specific

Comparative Biology

Evolutionary Conservation

Model Organisms

Clinical Presentation

Diagnostic Features

Disease Staging

Prevention Strategies